Feeds:
Posts
Comments

Search Results for 'Allergan'

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma   Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes.  It is […]

Read Full Post »

LIVE 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, Cambridge Reporter: Aviva Lev-Ari, PhD, RN Aviva Lev-Ari, PhD, RN at LPBI Group will cover the event in Real Time @pharma_BI @AVIVA1950 @USAIC #USAIC17 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, […]

Read Full Post »

M&A – New Rules in the Game: @Tulane University’s Law School, M&A Conference – Allergan Inc.’s $66 billion sale to Actavis PLC Reporter: Aviva Lev-Ari, PhD, RN The deal, Allergan Inc.’s $66 billion sale to Actavis PLC, closed on 3/22/2015, ahead of schedule and 11 months after Valeant Pharmaceuticals International Inc. and activist William Ackman’s hedge-fund firm had […]

Read Full Post »

BioGENEius GenePool Competition – the “nature and nurture” SHARK TANK® at Bio International Convention, June 19-22, 2017 | San Diego, CA Reporter: Aviva Lev-Ari, PhD, RN http://www.convention.bio.org/2017/   AGENDA BIO 2017 Schedule Arrive Sunday and Stay Until Friday! Take full advantage of BIO 2017! Partnering and Education kick off on Monday afternoon, and the BIO […]

Read Full Post »

Re-Creation of the Big Pharma Model via Transformational Deals for Accelerating Innovations: Licensing vs In-house inventions Reporter: Aviva Lev-Ari, PhD, RN SOURCE http://www.wsj.com/articles/teva-to-buy-allergan-generics-for-40-5-billion-1437988044 Teva-Allergan Buy Likely Heralds More Big Deals Teva’s acquisition of Allergan’s generic-drugs unit for $40.5 billion is likely to trigger more deal-making in the already-frenzied health-care sector. Bernstein analyst Ronny Gal said […]

Read Full Post »

Allergan agrees to $66 billion Actavis offer $219 a share Reporter: Aviva Lev-Ari, PhD, RN   (Reuters) – Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc. Dublin-based Actavis offered $219 per share in cash and stock, amounting […]

Read Full Post »

LIVE Day 1 – 2017 MassBio Annual Meeting  March 30, 2017 8:00 AM, Royal Sonesta Boston Reporter: Aviva Lev-Ari, PhD, RN   Real Time Coverage: Aviva Lev-Ari, PhD, RN #MassBioAM17 #PatientDriven @pharma_BI @AVIVA1950 Day 1 Breakfast and Registration 8:00 am – 9:00 am Welcome Remarks & MassBio Board Elections Plenary 9:00 am – 9:30 am […]

Read Full Post »

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017. Curator: Aviva Lev-Ari, PhD, RN UPDATED on 2/21/2021 The Announcement of the 2021 […]

Read Full Post »

  Two New Drugs for Inflammatory Bowel Syndrome Are Giving Patients Hope Reporter: Stephen J. Williams, Ph.D. Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults -First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea DUBLIN, May 27, 2015 […]

Read Full Post »

C. botulinum toxin activity Larry H. Bernstein, MD, FCAP, Curator LPBI     The botulinum toxin as a therapeutic agent: molecular and pharmacological insights Roshan Kukreja,1 Bal Ram Singh2 Dove  8 Dec 2015; Volume 2015: 5: 173—183 DOI http://dx.doi.org/10.2147/RRBC.S60432   Botulinum neurotoxins (BoNTs), the most potent toxins known to mankind, are metalloproteases that act on nerve–muscle junctions […]

Read Full Post »

« Prev - Next »

%d bloggers like this: